goldfinger
- 01 Sep 2004 15:33
This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.
Heres the latest news from Killik stocbrokers on the company..........
MEDICAL MARKETING Joint Venture
We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.
Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.
This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)
The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.
Please DYOR
cheers GF.
goldfinger
- 03 Feb 2005 11:53
- 183 of 2444
Wow just look at it go, up 14%, NICE.
cheers Gf
goldfinger
- 03 Feb 2005 12:16
- 184 of 2444
Superb chart.
cheers GF.
mitzy
- 03 Feb 2005 13:03
- 185 of 2444
My previous target was for 400p year end but I am erring on the side of caution as the sp has increased too fast in the last month and therefore I am reducing the target to 120p to 200p.
Longer term I see no problem with 400p to 500p.I recall IC stating that they were a possible 10 bagger at 60p;talk of 1000p and 1500p a share is fantasy.
moneyplus
- 03 Feb 2005 13:06
- 186 of 2444
goldfinger
- 03 Feb 2005 13:40
- 187 of 2444
two quid plus will do me.
cheers GF.
goldfinger
- 03 Feb 2005 14:18
- 188 of 2444
Some big buys coming in.
cheers Gf.
mitzy
- 03 Feb 2005 14:56
- 189 of 2444
Just being cautious GF.. look at all the buys today I've never seen so much action in MMI.. almost like panic buying..
goldfinger
- 03 Feb 2005 15:33
- 190 of 2444
I know ,its marvelous. 2 quid plus here we come.
cheers GF.
rob308
- 03 Feb 2005 20:15
- 191 of 2444
These are the largest volumes I have ever seen traded in MMG, this is on 'reasonable' news............ brace yourselves for when big news comes, maybe the granting of a license etc.
Keep it up........ Rob
andysmith
- 03 Feb 2005 21:06
- 192 of 2444
Glad I stuck with this one, a friend of mine got bored last week!!!! At least he put his money in SEO which is also flying, luckily for me I have both and thanks to gf also DGM not to mention my IDS, bloody great year so far and I expect MMG will deliver this year, any weakness at all and I'll have more, not yet though, sometimes this falls back in between news,
mitzy
- 04 Feb 2005 08:21
- 193 of 2444
What fall back it goes up every day..!
goldfinger
- 04 Feb 2005 11:48
- 194 of 2444
Going up like the clappers again. These are a big buy.
cheers GF.
goldfinger
- 04 Feb 2005 12:33
- 195 of 2444
Moving higher , now up over 11%.
cheers GF.
hlyeo98
- 04 Feb 2005 13:19
- 196 of 2444
28/01/2005 - MMI's ruthenium cancer therapy passes independently verified safety tests
Medical Marketing International Group plc (AIM:MMG), the Cambridge, UK-based pharmaceutical development company today announces that lead ruthenium compounds within its portfolio of cancer therapies show toxicity at an even safer level than tamoxifen, one of the safest cancer drugs currently available, when tested in an industry standard laboratory model.
Independent laboratory tests show ruthenium to have a low toxicity profile
Efficacy of ruthenium shown to be better than market-leading platinum drugs
Patents recently granted in biggest markets, USA and EU giving long patent protection. Other patents are pending.
MMI has already shown that the ruthenium cancer therapies within its wholly-owned subsidiary, Oncosense, appear in laboratory tests to be more powerful than the platinum-based drugs which have been some of the most successful cancer drugs for decades and which had peak sales of $5bn. Efficacy of these compounds has also been independently demonstrated in both human cancer cells and in vivo models. MMI recently announced that patents in USA and Europe, the two biggest markets have been granted, and other patents are pending.
MMI used the Dundee-based specialist, CXR Biosciences Ltd to test the most promising ruthenium compounds for potential toxicity. A summary of the CXR results is announced today.
Mark Burton, Technical Manager at MMI said: "We chose CXR because of their highly regarded expertise in screening new drugs for harmful effects. Not only did CXR deliver the results on time and on budget, they were able to show that our ruthenium cancer therapies demonstrate a low toxicity profile. These results, when added to the existing efficacy data show that ruthenium has great clinical potential."
Dr Cliff Elcombe Director at CXR and former Senior Scientist at Zeneca said: "We feel privileged to have been chosen by MMI to carry out the safety studies on what now appears to be an extremely interesting new class of cancer drugs. The safety screens that we performed indicate that this new group of cancer therapies has enormous potential."
Executive Chairman of MMI Group, David Best, commenting on these results said: "Ruthenium is only one of MMI's portfolio of excellent drug candidates, but already data show it to be potentially the most effective drug against serious cancers like lung, colon and ovarian. This new data from CXR shows ruthenium to be potentially relatively safe too. If these results are confirmed in the clinical trials, then ruthenium may improve significantly on the standard treatment for cancer patients and become a major commercial success in a cancer therapy market that was worth $42 billion in 2004 and continues to grow in double-digit figures."
mitzy
- 04 Feb 2005 13:20
- 197 of 2444
Killicks are pushing this one and NLR both of which I hold...perhaps old Kav has got it right this time around since the Tech collpase of 2000..?
goldfinger
- 04 Feb 2005 13:20
- 198 of 2444
Buys still coming in.
cheers GF.
goldfinger
- 04 Feb 2005 15:32
- 199 of 2444
A few taking weekend pocket money now. Great week for this one and should move up again next week.
cheers GF.
moneyplus
- 04 Feb 2005 21:42
- 200 of 2444
Sad to do it but I finally ditched boring PAY to add to SEO and MMG. GF are you still following PAY? I am hoping the pundits will finally wake up to this as another potential NLR but until then my money is off elsewhere!! cheers MP
goldfinger
- 05 Feb 2005 03:34
- 201 of 2444
Sure am MP but not putting any more funds in.
cheers GF.
goldfinger
- 07 Feb 2005 02:44
- 202 of 2444
I see Mike Walters on his site as given this one another good update after the Pru went in and increased its stake.
cheers GF.